Leaderboards/Bladder and Urothelial Cancer Treatments

Bladder and Urothelial Cancer Treatments

Last updated July 15, 2026

Rising Stars

Fresh ink, massive impact

Researchers

1
Ian M. McElree
Vanderbilt University Medical Center
2
Sia V. Lindskrog
Aarhus University
3
Mattia Longoni
Vita-Salute San Raffaele University
4
Florus C. de Jong
Erasmus MC Cancer Institute
5
M. Roupret
Institut Universitaire de France
6
Trine Strandgaard
Aarhus University
7
Jacobi Hines
Northwestern University
8
Kenneth Gouin
Joint Center for Structural Genomics
9
Bérengère Salomé
Icahn School of Medicine at Mount Sinai
10
Yuki Arita
Memorial Sloan Kettering Cancer Center

Papers

1
Evaluation of Major Pathologic Response and Pathologic Complete Response as Surrogate End Points for Survival in Randomized Controlled Trials of Neoadjuvant Immune Checkpoint Blockade in Resectable in NSCLC
Journal of Thoracic Oncology|2024
74 cit.
2
Publication in Asian journal of urology (2025) [25 citations, W4407818742]
Asian journal of urology|2025
25 cit.
3
Use of 18F‐fluoro‐2‐deoxy‐ <scp>d</scp> ‐glucose <scp>(18F‐FDG) PET</scp> / <scp>CT</scp> for lymph node assessment before radical cystectomy in bladder cancer patients
British Journal of Urology|2024
24 cit.
4
Publication in Insights into Imaging (2025) [24 citations, W4406001403]
Insights into Imaging|2025
24 cit.
5
Survival Outcomes and Temporal Trends of Non-Surgical Management Vs Radical Cystectomy in Non-Organ-Confined Urothelial Bladder Cancer
Urology|2025
21 cit.
6
Contemporary outcomes in non‐muscle‐invasive bladder cancer: a large European multicentre study
British Journal of Urology|2025
19 cit.
7
Survival after trimodal therapy in octogenarians with organ‐confined urothelial bladder cancer
British Journal of Urology|2024
16 cit.
8
Publication in Clinical Genitourinary Cancer (2025) [9 citations, W4406169109]
Clinical Genitourinary Cancer|2025
9 cit.
9
PD-L1 expression in high-risk non-muscle invasive bladder cancer is not a biomarker of response to BCG
World Journal of Urology|2025
8 cit.
10
Publication in Cancers (2024) [7 citations, W4400735017]
Cancers|2024
7 cit.

Emerging Leaders

Drafting the new consensus

Researchers

1
David Mallery
Translational Genomics Research Institute
2
John A. Demchok
National Cancer Institute
3
Laxmi Lolla
Windber Research Institute
4
Lisa A. Gurski
National Comprehensive Cancer Network
5
Aurélie Kamoun
La Ligue Contre le Cancer
6
Alexandre Zlotta
University of Toronto
7
Charlotte F. Kweldam
Maasstad Ziekenhuis
8
Alyse Johnson-Chilla
National Comprehensive Cancer Network
9
Michelle R. Downes
Sunnybrook Health Science Centre
10
Ning Liu
Hainan General Hospital

Papers

1
Rectal Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network|2022
819 cit.
2
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Journal of the National Comprehensive Cancer Network|2022
302 cit.
3
Bladder Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
236 cit.
4
NCCN Guidelines® Insights: Rectal Cancer, Version 3.2024
Journal of the National Comprehensive Cancer Network|2024
215 cit.
5
NCCN Guidelines® Insights: Kidney Cancer, Version 2.2024
Journal of the National Comprehensive Cancer Network|2024
166 cit.
6
HuR confers IL-17a-induced migration and invasion of gastric cancer cells via upregulation of Snail translation
Cytokine|2022
28 cit.
7
The impact of grading scheme on non-muscle invasive bladder cancer progression: potential utility of hybrid grading schemes
Pathology|2022
19 cit.
8
Epidemic, risk factors of carbapenem-resistant Klebsiella pneumoniae infection and its effect on the early prognosis of liver transplantation
Frontiers in Cellular and Infection Microbiology|2022
16 cit.
9
Impact of cribriform pattern 4 and intraductal prostatic carcinoma on National Comprehensive Cancer Network (NCCN) and Cancer of Prostate Risk Assessment (CAPRA) patient stratification
Modern Pathology|2022
13 cit.
10
International Society of Urological Pathology (ISUP) Consensus Conference on Current Issues in Bladder Cancer. Working Group 1
The American Journal of Surgical Pathology|2023
12 cit.

Current Senior Leaders

Wrote the book, still writing it

Researchers

1
Shahrokh F. Shariat
Universitätszahnklinik Wien
2
Dean F. Bajorin
Memorial Sloan Kettering Cancer Center
3
Donald G. Skinner
Stellenbosch University
4
Seth P. Lerner
Baylor College of Medicine
5
Thomas Powles
Queen Mary University of London
6
Richard Sylvester
European Organisation for Research and Treatment of Cancer
7
Pierre I. Karakiewicz
Université de Montréal
8
Margaret A. Knowles
St James's University Hospital
9
Colin P. Dinney
The University of Texas MD Anderson Cancer Center
10
Matthew D. Galsky
Icahn School of Medicine at Mount Sinai

Papers

1
TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Nature|2018
5.5k cit.
2
Radical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Journal of Clinical Oncology|2001
3.5k cit.
3
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
New England Journal of Medicine|2017
3.4k cit.
4
Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC Trials
European Urology|2006
3k cit.
5
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Cell|2017
2.5k cit.
6
Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial
The Lancet|2016
2.2k cit.
7
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
The Lancet Oncology|2017
1.7k cit.
8
Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial
The Lancet|2001
1.4k cit.
9
European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcinoma: 2015 Update
European Urology|2015
1.3k cit.
10
WHO handbook for reporting results of cancer treatment
Controlled Clinical Trials|1980
1.1k cit.

Reagents for Bladder and Urothelial Cancer Treatments

Citation-validated products used in this field

🔥 Trending

Gaining adoption fast

⭐ Top Rated

Best all-around

Cell Signaling TechnologyEvidence 66

Progesterone Receptor A/B (D8Q2J) Rabbit Monoclonal Antibody (BSA and Azide Free)

Cited in 5 papers
#18444$865
View Evidence →
Cell Signaling Technology

Tri-Methyl-Ezh2 (Lys509) (F1D1Q) Rabbit Monoclonal Antibody

Cited in 5 papers
#9994$176,437
View Evidence →
Cell Signaling TechnologyEvidence 66

SH3BP4 (D3D9I) Rabbit Monoclonal Antibody

Cited in 5 papers
#55935$161,351
View Evidence →

🌟 All-Time

Most validated

Cell Signaling Technology

ZFP36L1 (E6L6S) Rabbit Monoclonal Antibody

Cited in 7 papers
#30894$161,351
View Evidence →
Cell Signaling TechnologyEvidence 66

MAML1 Antibody

Cited in 6 papers
#4608$317
View Evidence →
Cell Signaling TechnologyEvidence 67

DNA-PKcs Antibody

Cited in 5 papers
#4602$135,314
View Evidence →